急性失代偿性心力衰竭：当代医学管理
Acute decompensated heart failure: contemporary medical management.
作者信息
Joseph Susan M, Cedars Ari M, Ewald Gregory A, Geltman Edward M, Mann Douglas L
机构信息
Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
出版信息
Tex Heart Inst J. 2009;36(6):510-20.
Abstract
Hospitalizations for acute decompensated heart failure are increasing in the United States. Moreover, the prevalence of heart failure is increasing consequent to an increased number of older individuals, as well as to improvement in therapies for coronary artery disease and sudden cardiac death that have enabled patients to live longer with cardiovascular disease. The main treatment goals in the hospitalized patient with heart failure are to restore euvolemia and to minimize adverse events. Common in-hospital treatments include intravenous diuretics, vasodilators, and inotropic agents. Novel pharmaceutical agents have shown promise in the treatment of acute decompensated heart failure and may simplify the treatment and reduce the morbidity associated with the disease. This review summarizes the contemporary management of patients with acute decompensated heart failure.
摘要
在美国，急性失代偿性心力衰竭的住院人数正在增加。此外，由于老年人口数量增加，以及冠状动脉疾病和心源性猝死治疗方法的改进使患者能够在患有心血管疾病的情况下活得更长，心力衰竭的患病率也在上升。心力衰竭住院患者的主要治疗目标是恢复血容量正常并尽量减少不良事件。常见的院内治疗包括静脉注射利尿剂、血管扩张剂和正性肌力药物。新型药剂在急性失代偿性心力衰竭的治疗中已显示出前景，可能会简化治疗并降低与该疾病相关的发病率。本综述总结了急性失代偿性心力衰竭患者的当代管理方法。
相似文献
1
Acute decompensated heart failure: contemporary medical management.
Tex Heart Inst J. 2009;36(6):510-20.
2
Diagnostic and therapeutic approach to acute decompensated heart failure.
Am J Med. 2007 Feb;120(2):121-7. doi: 10.1016/j.amjmed.2006.05.066.
3
[Pharmacotherapy of acute heart failure: update and perspectives].
Dtsch Med Wochenschr. 2012 May;137(21):1126-9. doi: 10.1055/s-0032-1304965. Epub 2012 May 15.
4
The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database.
Am Heart J. 2007 Aug;154(2):267-77. doi: 10.1016/j.ahj.2007.04.033.
5
Acute decompensated heart failure.
Cardiol Clin. 2012 Nov;30(4):665-71. doi: 10.1016/j.ccl.2012.07.006. Epub 2012 Sep 20.
6
The treatment targets in acute decompensated heart failure.
Rev Cardiovasc Med. 2001;2 Suppl 2:S7-S12.
7
Acute decompensated heart failure: best evidence and current practice.
Minerva Cardioangiol. 2005 Dec;53(6):537-47.
8
Medical therapy for acute decompensated heart failure: what recent clinical trials have taught us about diuretics and vasodilators.
Curr Heart Fail Rep. 2012 Mar;9(1):1-7. doi: 10.1007/s11897-011-0072-6.
9
Pathophysiology of chronic heart failure.
Am J Med. 2001 May 7;110 Suppl 7A:37S-46S. doi: 10.1016/s0002-9343(98)00385-4.
10
Management of acute decompensated heart failure.
CMAJ. 2007 Mar 13;176(6):797-805. doi: 10.1503/cmaj.051620.
引用本文的文献
1
Arterial stiffness in acute decompensated heart failure and acute kidney injury: a prospective observational cohort study protocol in a tertiary hospital setting.
BMJ Open. 2025 Jun 23;15(6):e097718. doi: 10.1136/bmjopen-2024-097718.
2
Acoustic features are independently associated with heart failure and pulmonary hypertension.
ESC Heart Fail. 2025 Aug;12(4):2946-2957. doi: 10.1002/ehf2.15309. Epub 2025 Apr 28.
3
Association between oral loop diuretics duration before discharge and hospital readmission in acute decompensated heart failure: A multicenter retrospective cohort study.
Medicine (Baltimore). 2024 Dec 6;103(49):e40834. doi: 10.1097/MD.0000000000040834.
4
Effect of Post-Loop Diuretic Urinary Sodium Level on Length of Stay and Rehospitalization in Acutely Decompensated Heart Failure Patients.
Cardiol Res. 2024 Oct;15(5):350-357. doi: 10.14740/cr1696. Epub 2024 Sep 16.
5
Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment.
J Vis Exp. 2024 Aug 2(210). doi: 10.3791/66624.
6
Prognostic utility of B-type natriuretic peptide and 6-min walk test in patients with acute decompensated heart failure.
Indian Heart J. 2024 Jul-Aug;76(4):291-296. doi: 10.1016/j.ihj.2024.07.011. Epub 2024 Jul 26.
7
Establishment of in-hospital nutrition support program for middle-aged and elderly patients with acute decompendated heart failure.
BMC Cardiovasc Disord. 2024 May 18;24(1):259. doi: 10.1186/s12872-024-03887-y.
8
Associations between static and dynamic changes of platelet counts and in-hospital mortality in critical patients with acute heart failure.
Sci Rep. 2024 Apr 21;14(1):9147. doi: 10.1038/s41598-024-59892-w.
9
Atrial Flutter in the Elderly Patient: The Growing Role of Ablation in Treatment.
Cureus. 2023 Dec 7;15(12):e50096. doi: 10.7759/cureus.50096. eCollection 2023 Dec.
10
MicroRNAs: Midfielders of Cardiac Health, Disease and Treatment.
Int J Mol Sci. 2023 Nov 11;24(22):16207. doi: 10.3390/ijms242216207.
本文引用的文献
1
Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
Lancet. 2009 Apr 25;373(9673):1429-39. doi: 10.1016/S0140-6736(09)60622-X. Epub 2009 Mar 28.
2
Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial.
J Card Fail. 2009 Apr;15(3):182-90. doi: 10.1016/j.cardfail.2009.01.008. Epub 2009 Mar 9.
3
Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure.
Hypertension. 2009 Feb;53(2):236-42. doi: 10.1161/HYPERTENSIONAHA.108.125278. Epub 2008 Dec 15.
4
Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
J Card Fail. 2008 Oct;14(8):641-7. doi: 10.1016/j.cardfail.2008.06.003. Epub 2008 Jul 10.
5
The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
J Card Fail. 2008 Oct;14(8):631-40. doi: 10.1016/j.cardfail.2008.08.010. Epub 2008 Sep 14.
6
Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis.
J Am Coll Cardiol. 2008 Aug 12;52(7):534-40. doi: 10.1016/j.jacc.2008.05.010.
7
Heart failure-related hospitalization in the U.S., 1979 to 2004.
J Am Coll Cardiol. 2008 Aug 5;52(6):428-34. doi: 10.1016/j.jacc.2008.03.061.
8
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.
Circulation. 2008 Jul 22;118(4):410-21. doi: 10.1161/CIRCULATIONAHA.108.765289.
9
Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program.
J Am Coll Cardiol. 2008 Jul 15;52(3):190-9. doi: 10.1016/j.jacc.2008.03.048.
10
Renal effects of ularitide in patients with decompensated heart failure.
Am Heart J. 2008 Jun;155(6):1012.e1-8. doi: 10.1016/j.ahj.2008.02.011.
Zotero 插件